DANIEL N. SAUDER

Toronto Canada
647-678-5579
daniel.sauder@gmail.com

PROFESSIONAL SUMMARY

Physician-executive and dermatology leader with 40+ years spanning academic department leadership, industry clinical development, and board service. Former Noxell Professor and Chairman of Dermatology at Johns Hopkins, Professor and Chief of Dermatology at the University of Toronto, Senior Vice President of Clinical Development at Dr. Reddy's Laboratories, and Vice President of Clinical Development at Excaliard Pharmaceuticals. Principal investigator on Phase I through Phase III dermatology trials in psoriasis, atopic dermatitis, cutaneous T-cell lymphoma, and rosacea. Scientific advisor to Amgen, Genentech, Biogen-Idec, Centocor, and 3M Pharmaceuticals. Senior Consultant to Halozyme Therapeutics (2009-2016). Senior Physician at Avenue Road Dermatology Group (2026-Present). Author of 140+ peer-reviewed articles. Strengths: clinical development strategy, trial design and interpretation, regulatory positioning, dermatologist and key opinion leader engagement, and constructive challenge of management.

CORE SKILLS

- Clinical development strategy
- Clinical trial design and conduct (Phase I-IV)
- Psoriasis
- Atopic dermatitis
- Topical and biologic therapies
- Cutaneous T-cell lymphoma
- Rosacea
- Regulatory strategy
- Clinical safety and tolerability evaluation
- Key opinion leader engagement
- Investigator relations
- Academic department leadership
- Corporate governance
- Scientific advisory
- Biologics coverage and reimbursement
- Grant funding
- Peer review and editorial leadership
- Mentoring

PROFESSIONAL EXPERIENCE

AVENUE ROAD DERMATOLOGY GROUP
Toronto, Ontario

Senior Physician 10/2026 - Present

- Senior physician in a four-physician dermatology practice in a new 16,000 sq ft office, [add: number of exam rooms, services, or patient capacity].
- Provide clinical dermatology care for inflammatory and chronic skin disease, maintaining direct engagement with current prescriber and patient perspectives.

TORONTO DERMATOLOGY CENTRE
Toronto, Ontario

Dermatologist 01/2018 - 09/2026

- Provided clinical dermatology care and maintained active engagement with current clinical practice and prescriber perspectives.

HALOZYME THERAPEUTICS INC.
San Diego, California

Senior Consultant 01/2009 - 01/2016

- Advised on dermatology product development, [measured by specific deliverables or programs], by providing scientific and clinical guidance.
- Co-authored research on a recombinant human hyaluronidase sustained-release gel for post-surgical edema.

PRINCETON UNIVERSITY HOSPITAL
Princeton, New Jersey

Head of Dermatology 01/2010 - 01/2013

- Led the dermatology service, measured by staff, patient volume, or program growth.

EXCALIARD PHARMACEUTICALS
Carlsbad, California

Vice President, Clinical Development 01/2007 - 01/2008

- Led clinical development planning, measured by IND or trial milestones achieved.

JOHNSON & JOHNSON

Consultant 01/2007 - 01/2008

- Provided clinical and regulatory consulting.

REGULATORY ASSOCIATES INC.

Consultant 11/2005 - 12/2007

- Provided clinical and regulatory consulting.

JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Baltimore, Maryland

Noxell Professor and Chairman, Department of Dermatology 07/2001 - 01/2005

- Led an academic dermatology department, [measured by faculty size, budget, or research growth], by setting departmental strategy.
- Contributed to institutional governance through the Johns Hopkins Medical Board, Clinical Directors Committee, Contracting Committee, Advisory Board of the Medical Faculty, and Clinical Research Building II Planning Council.

DR. REDDY'S LABORATORIES INC.
Bridgewater, New Jersey

Senior Vice President, Clinical Development 07/2005

- Directed clinical development strategy by overseeing trial design, regulatory interactions, and cross-functional execution.

UNIVERSITY OF TORONTO
Toronto, Ontario

Professor and Chief, Division of Dermatology 07/1982 - 06/2001

- Advanced a novel angiogenesis inhibitor (AE-941, Neovastat) to clinical proof of concept in plaque psoriasis, measured by a randomized Phase I/II trial published in the Journal of the American Academy of Dermatology (2002), as principal investigator.
- Led a Phase III pediatric atopic dermatitis trial of tacrolimus ointment (Fujisawa, 1997-98) as principal investigator, followed by a long-term open-label pediatric safety follow-up (1999-2000).
- Contributed to a 12-month safety and efficacy study of pimecrolimus (SDZ ASM 981) cream in atopic dermatitis as co-investigator.
- Assessed topical safety and efficacy in psoriasis through comparative calcipotriol and corticosteroid atrophogenicity studies (Leo Laboratories) as principal investigator.
- Led trials in cutaneous T-cell lymphoma (DAB389IL-2 Phase III; Targretin Phase 2-3), rosacea, and onychomycosis for industry sponsors including Seragen, Ligand, GenDerm, and Sandoz.
- Secured peer-reviewed research funding, measured by $384,423 and $205,320 in Medical Research Council direct costs as principal investigator.
- Directed the General Research Program at Sunnybrook Health Science Centre (1993-1996) and chaired the Decanal Promotions Committee (1997-2000).

MCMASTER UNIVERSITY
Hamilton, Ontario

Faculty, Division of Dermatology 01/1982 - 01/1990

- Progressed from Assistant Professor (1982-1985) to Associate Professor (1985-1990) to Professor (1990).

EDUCATION

VISITING ASSOCIATE: DERMATOLOGY BRANCH 01/1982
National Cancer Institute, NIH, Bethesda, Maryland

DERMATOLOGY RESIDENCY 01/1979
Cleveland Clinic, Cleveland, Ohio

MEDICAL INTERNSHIP 01/1976
Royal Victoria Hospital, McGill University, Montreal

M.D. 01/1975
McMaster University, Hamilton, Ontario

M.A.: MATHEMATICS 01/1972
York University, Toronto, Ontario

B.A.: HONORS MATHEMATICS 01/1971
York University, Toronto, Ontario

CERTIFICATIONS

- Diplomate, American Board of Dermatology (1980)
- American Board of Internal Medicine (1978)
- Fellow, Royal College of Physicians and Surgeons of Canada (1980)
- Fellow, American College of Physicians (1981)
- Fellow, American Academy of Dermatology (1983)

AWARDS & RECOGNITION

Elected, American Society for Clinical Investigation (1992), American Melanoma Foundation Physician Recognition Award (2005), Young Leadership Award, American Dermatological Association (1984), Province of Ontario Career Scientist Award (1982), Israel Zeligman Memorial Lecturer (2002)

SELECTED PRESENTATIONS

- "Immune Pathogenesis of Psoriasis: Role of Biologic Therapies," Visiting Professor, New York University Medical Center, Oct 2003
- "Angiogenesis Antagonists as Treatment for Psoriasis," Visiting Professor, St. Thomas' Hospital, London, Nov 1999
- "Angiogenesis Antagonists as Treatment for Psoriasis: Phase 1 Clinical Trial Results with AE-941," 2nd Annual International Psoriasis Symposium, Sep 1998
- "Molecular Mechanisms in the Cutaneous Inflammatory Response," Keynote Speaker, Society of Cosmetic Chemists, Dec 1998
- "Structure and Function of the Skin: Epidermal Cytokines," American Academy of Dermatology, Feb 2005

BOARD AND ADVISORY EXPERIENCE

- Board of Directors, Baycrest Hospital (the largest senior care hospital in North America) (2023-Present).
- Board of Directors: Welichem Biotech (2004); Seragen Biopharmaceuticals (1995-1996); Stiefel International Corporation (1994-1996) [confirm spelling and role].
- President, Canadian Dermatology Association (1997-1998).
- Founding President, Canadian Society for Investigative Dermatology; Chairman, Committee on Finances, Society for Investigative Dermatology (1999-2001).
- Scientific Advisory Boards: QLT (2005-2007); Aeterna Laboratories (1995-2001); American Melanoma Foundation (2005-Present); Intercon Pharma (1988-1990).
- Scientific Advisor: 3M Pharmaceuticals (1991-2001); Biogen-Idec, Amgen, Centocor, Genentech (2001-2004).
- Editor-in-Chief, Journal of Cutaneous Medicine and Surgery; editorial board member for multiple dermatology journals.

PATENTS AND PUBLICATIONS

Inventor on multiple patent disclosures and applications (1997-2001). 140+ peer-reviewed articles, 30 clinical reviews, and 35 book chapters. Full list available on request.